Become a Partner

From Discovery to Development—Faster

Reprogramming Protein Fate with Induced Proximity

Unlocking new therapeutic possibilities beyond CRBN and VHL through a next-generation proximity platform. At GenProtex, our mission is to transform how therapeutics are discovered and developed using induced proximity.

Start a conversation
Redefining Proximity-Based Medicine

Our proprietary Bio-orthogonal Proximity Induction (BPI) platform enables precise control of protein interactions, opening new pathways for degradation, stabilization, and functional modulation.

The Problem

A Powerful Modality, Limited by Biology

Targeted Protein Degradation (TPD) has enormous potential, but progress is constrained:

 

  • Limited E3 ligase access
    Most therapies rely on just two ligases (CRBN and VHL), leaving hundreds untapped.
  • Slow and complex discovery
    Traditional approaches require time-consuming ligand design and structural validation.
  • Off-target risk
    Widely expressed ligases increase unintended activity in healthy tissues.
Get in touch

Our Solution

A New Way to Unlock E3 Ligases

GenProtex’s BPI platform enables controlled, ligand-independent protein proximity directly in living cells.

What makes it different:

 

  • Ligand-independent discovery
    Identify productive interactions before investing in chemistry.
  • Site-specific precision
    Map optimal interaction sites at single-residue resolution.
  • Rapid in-cell validation
    Observe functional protein degradation within hours.
  • Scalable across ligases and beyond
    Expand beyond E3 ligases to broader proximity-based systems.
Partner with us

How it works

Unlocking new therapeutic possibilities beyond CRBN and VHL through a next-generation proximity platform. At GenProtex, our mission is to transform how therapeutics are discovered and developed using induced proximity.

Got a question?

STEP 1

Identification of potential effectors

GenProtex applies activity‑based probes (ABPs) to identify functionally active E3 ligases within target cells and tissues.

STEP 2

Effector and binding‑site selection

In‑cellulo surface profiling using the BPI platform enables assessment of which effector surfaces support small‑molecule recruitment and productive ternary complex formation.

STEP 3

GenProtex

Outcome

Selection of optimal effector(s) and binding site(s) to enable focused screening and fast‑tracked compound development.

Our Expert Team

The founding team brings deep scientific expertise and decades of experience across academic discovery, drug development, platform innovation, and biotech leadership.

Contact our team

Ricardo Moreno Ballesteros

Scientific founder

View More

Prof. Satpal Virdee

Scientific Advisor

View More

Isabel
Dodd

Commercial Advisor

View More

Jason
Mundin

Commercial Advisor

View More

Build the Future of Therapeutics Together

We partner at the earliest stages to unlock new opportunities in proximity-based medicine.

We would be pleased to:

  • Explore strategic fit through discussion

  • Share platform data and development roadmap

  • Define co-development, licensing, or investment pathways

Our platform has demonstrated strong proof-of-concept in targeted protein degradation, enabling efficient recruitment of E3 ligases to therapeutic targets. We support programmes focused on identifying and validating novel E3 ligases and targets for TPD, while also enabling exploration of non-TPD induced proximity applications.